Related references
Note: Only part of the references are listed.Natural Product Synthesis: Changes over Time
Reinhard W. Hoffmann
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
A Continuous-Flow Process for the Synthesis of Artemisinin
Daniel Kopetzki et al.
CHEMISTRY-A EUROPEAN JOURNAL (2013)
Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
Stephan A. Veltkamp et al.
CLINICAL DRUG INVESTIGATION (2013)
High-level semi-synthetic production of the potent antimalarial artemisinin
C. J. Paddon et al.
NATURE (2013)
Maturing antibody-drug conjugate pipeline hits 30
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
Structural selectivity of human SGLT inhibitors
Charles S. Hummel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Merging Chemical Synthesis and Biosynthesis: A New Chapter in the Total Synthesis of Natural Products and Natural Product Libraries
Andreas Kirschning et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Continuous-Flow Synthesis of the Anti-Malaria Drug Artemisinin
Francois Levesque et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Stephanie S. Minich
ANNALS OF PHARMACOTHERAPY (2012)
Further Insights into the Mode of Action of the Lipoglycopeptide Telavancin through Global Gene Expression Studies
Yang Song et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic
Trudy H. Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
Masakazu Imamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Insights into the pharmacological relevance of lysophospholipid receptors
Tetsuji Mutoh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Recent advances in the synthesis of new glycopeptide antibiotics
Polly-Anna Ashford et al.
CHEMICAL SOCIETY REVIEWS (2012)
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2012)
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
Jens Ingwersen et al.
CLINICAL IMMUNOLOGY (2012)
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Muhammad A. Abdul-Ghani et al.
CURRENT DIABETES REPORTS (2012)
Effects of SGLT2 inhibitors on cardiovascular outcomes
Celine Foote et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
G. Luippold et al.
DIABETES OBESITY & METABOLISM (2012)
The incretin hormones: from scientific discovery to practical therapeutics
S. Mudaliar et al.
DIABETOLOGIA (2012)
Novel GLP-1 receptor agonists for diabetes
Alan J. Garber
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
William N. Washburn
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
mTOR kinase inhibitors as a treatment strategy in hematological malignancies
Olga Grzybowska-Izydorczyk et al.
FUTURE MEDICINAL CHEMISTRY (2012)
SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Raktim Kumar Ghosh et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Roger B. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Yoshihito Ohtake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent
Xiao-Yi Xiao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2012)
Total Synthesis of [Ψ[C(=S)NH]Tpg4]Vancomycin Aglycon, [Ψ[C(=NH)NH]Tpg4]Vancomycin Aglycon, and Related Key Compounds: Reengineering Vancomycin for Dual D-Ala-D-Ala and D-Ala-D-Lac Binding
Jian Xie et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
Atsuo Tahara et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Fingolimod for Multiple Sclerosis
Daniel Pelletier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
INFECTIOUS DISEASES Can New Chemistry Make a Malaria Drug Plentiful and Cheap?
Kai Kupferschmidt
SCIENCE (2012)
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Brian L. Furman
TOXICON (2012)
Biosynthetic medicinal chemistry of natural product drugs
Frank E. Koehn
MEDCHEMCOMM (2012)
Small molecules targeting phosphoinositide 3-kinases
Peng Wu et al.
MEDCHEMCOMM (2012)
Drug discovery and development: lessons from an undeveloped drug
Toufigh Gordi
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2012)
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
Masayuki Suzuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?
Philippe Aftimos et al.
ADVANCES IN THERAPY (2011)
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Shannon L. Holt et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
Murray J. Towle et al.
CANCER RESEARCH (2011)
Artemisinin: Discovery from the Chinese Herbal Garden
Louis H. Miller et al.
CELL (2011)
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Howard A. Burris et al.
CLINICAL BREAST CANCER (2011)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
M. Pfister et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Discovery of Antibacterials and Other Bioactive Compounds from Microorganisms- Evaluating Methodologies for Discovery and Generation of Non-Ribosomal Peptide Antibiotics
K. Witting et al.
CURRENT DRUG TARGETS (2011)
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
E. Ciraolo et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
S. J. Shuttleworth et al.
CURRENT MEDICINAL CHEMISTRY (2011)
ATP-Competitive Inhibitors of mTOR: An Update
S. Schenone et al.
CURRENT MEDICINAL CHEMISTRY (2011)
The Chemical Biology of Immunophilin Ligands
S. Gaali et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Natural products as catalysts for innovation: a pharmaceutical industry perspective
Esther K. Schmitt et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2011)
Glycopeptide Antibiotics and their Novel Semi-Synthetic Derivatives
Marimuthu Jeya et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
The State of the Art in Anti-Malarial Drug Discovery and Development
Jeremy N. Burrows et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Sherwyn L. Schwartz et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Echinocandin Antifungal Drugs in Fungal Infections A Comparison
Sharon C. -A. Chen et al.
DRUGS (2011)
Pharmacokinetic and pharmacodynamic evaluation of tigecycline
Helen Giamarellou et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Qian Zhou et al.
FUTURE ONCOLOGY (2011)
Antibiotics in the clinical pipeline in 2011
Mark S. Butler et al.
JOURNAL OF ANTIBIOTICS (2011)
Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeted Drug Delivery Using Immunoconjugates: Principles and Applications
Maria Valentina Pasquetto et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite
Cherilyn R. Strader et al.
JOURNAL OF NATURAL PRODUCTS (2011)
A Redesigned Vancomycin Engineered for Dual D-Ala-D-Ala and D-Ala-D-Lac Binding Exhibits Potent Antimicrobial Activity Against Vancomycin-Resistant Bacteria
Jian Xie et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
SGLT2 inhibitors: molecuar design and potential differences in effect
Masayuki Isaji
KIDNEY INTERNATIONAL (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Natural products and Pharma 2011: Strategic changes spur new opportunities
Guy T. Carter
NATURAL PRODUCT REPORTS (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A Hydrogen Peroxide Based Access to Qinghaosu (Artemisinin)
Hong-Dong Hao et al.
ORGANIC LETTERS (2011)
Metabolic engineering of artemisinin biosynthesis in Artemisia annua L.
Benye Liu et al.
PLANT CELL REPORTS (2011)
Microbial production of isoprenoids
Sunil S. Chandran et al.
PROCESS BIOCHEMISTRY (2011)
Methodological advances permit the stereocontrolled construction of diverse fully synthetic tetracyclines containing an all-carbon quaternary center at position C5a
Peter M. Wright et al.
TETRAHEDRON (2011)
A practical, convergent route to the key precursor to the tetracycline antibiotics
David A. Kummer et al.
CHEMICAL SCIENCE (2011)
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
David A. Fruman et al.
CANCER DISCOVERY (2011)
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with Type 2 diabetes mellitus
John E Gerich et al.
Expert Review of Clinical Pharmacology (2011)
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
Timothy Colin Hardman et al.
Diabetes Therapy (2011)
Neurological S1P Signaling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis
Chang Wook Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2010)
An Expeditious Route to Fluorinated Rapamycin Analogues by Utilising Mutasynthesis
Rebecca J. M. Goss et al.
CHEMBIOCHEM (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Dapagliflozin: more than just another oral glucose-lowering agent?
Niki Katsiki et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Biosynthesis of rapamycin and its regulation: past achievements and recent progress
Sung Ryeol Park et al.
JOURNAL OF ANTIBIOTICS (2010)
Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning
Trung H. M. Pham et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Ziconotide for treatment of severe chronic pain
Achim Schmidtko et al.
LANCET (2010)
Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
Manu Lopus et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The Biosynthesis of Artemisinin (Qinghaosu) and the Phytochemistry of Artemisia annua L. (Qinghao)
Geoffrey D. Brown
MOLECULES (2010)
Natural product mode of action (MOA) studies: a link between natural and synthetic worlds
James J. La Clair
NATURAL PRODUCT REPORTS (2010)
Demand for malaria drug soars
Richard Van Noorden
NATURE (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Liraglutide
Daniel J. Drucker et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin
Michael T. Guskey et al.
PHARMACOTHERAPY (2010)
A concise stereoselective total synthesis of (+)-artemisinin
J. S. Yadav et al.
TETRAHEDRON (2010)
The Biosynthetic Logic of Polyketide Diversity
Christian Hertweck
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
From nature to the laboratory and into the clinic
K. C. Nicolaou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
The Halichondrins and E7389
Katrina L. Jackson et al.
CHEMICAL REVIEWS (2009)
Total Synthesis of Rapamycin
Steven V. Ley et al.
CHEMISTRY-A EUROPEAN JOURNAL (2009)
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2009)
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
Renate E. van Genugten et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective
Salvatore Brugaletta et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
William N. Washburn
JOURNAL OF MEDICINAL CHEMISTRY (2009)
New Syntheses of E7389 C14-C35 and Halichondrin C14-C38 Building Blocks: Reductive Cyclization and Oxy-Michael Cyclization Approaches
Cheng-Guo Dong et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
The incretin system and its role in type 2 diabetes mellitus
Jens Juul Holst et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Discovery of Artemisinin (Qinghaosu)
Fulong Liao
MOLECULES (2009)
Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs
Edmund I. Graziani
NATURAL PRODUCT REPORTS (2009)
Development of Yondelis (R) (trabectedin, ET-743). A semisynthetic process solves the supply problem
Carmen Cuevas et al.
NATURAL PRODUCT REPORTS (2009)
Conotoxins: natural product drug leads
Reena Halai et al.
NATURAL PRODUCT REPORTS (2009)
Flexible tetracycline synthesis yields promising antibiotics
Martin D. Burke
NATURE CHEMICAL BIOLOGY (2009)
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Florian Mullershausen et al.
NATURE CHEMICAL BIOLOGY (2009)
Drug development from marine natural products
Tadeusz F. Molinski et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Everolimus
Michael B. Atkins et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Telavancin
G. Ralph Corey et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli
Hiroko Tsuruta et al.
PLOS ONE (2009)
Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations
Joseph P. Boni et al.
SEMINARS IN ONCOLOGY (2009)
Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth
James J. Gibbons et al.
SEMINARS IN ONCOLOGY (2009)
Novel echinocandin antifungals. Part 1: Novel side-chain analogs of the natural product FR901379
Masaki Tomishima et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin
Masaki Tomishima et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
Bruce A. Ellsworth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Options for the treatment of patients with taxane-refractory metastatic breast cancer
Beth Overmoyer
CLINICAL BREAST CANCER (2008)
The chemistry and biology of the maytansinoid antitumor agents
Andreas Kirschning et al.
COMPTES RENDUS CHIMIE (2008)
New agents in development for the treatment of bacterial infections
Darren Abbanat et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Dapagliflozin. SGLT2 inhibitor, Antidiabetic agent
P. Cole et al.
DRUGS OF THE FUTURE (2008)
Optimizing natural products by biosynthetic engineering: Discovery of nonquinone Hsp90 inhibitors
Ming-Qiang Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis, in Staphylococcus aureus
Sung Joon Kim et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
A Robust Platform for the Synthesis of New Tetracycline Antibiotics
Cuixiang Sun et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: combining synthetic chemistry and biosynthetic engineering for diversifying natural products
Jonathan Kennedy
NATURAL PRODUCT REPORTS (2008)
Natural products to drugs: natural product-derived compounds in clinical trials
Mark S. Butler
NATURAL PRODUCT REPORTS (2008)
Making artemisinin
Patrick S. Covello
PHYTOCHEMISTRY (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Qinghaosu (Artemisinin): The price of success
N. J. White
SCIENCE (2008)
Binding of rapamycin analogs to channels and FKBP52 contributes their neuroprotective activities
Benfang Ruan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Eribulin mesilate - Antimitotic drug tubulin polymerization inhibitor oncolytic
Y. Wang et al.
DRUGS OF THE FUTURE (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
New concepts in the treatment of type 2 diabetes
J. J. Meier et al.
INTERNIST (2007)
Functional genomics and the biosynthesis of artemisinin
Patrick S. Covello et al.
PHYTOCHEMISTRY (2007)
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate
Rajita Pappu et al.
SCIENCE (2007)
Discovery of micafungin (FK463): A novel antifungal drug derived from a natural product lead
Akihiko Fujie
PURE AND APPLIED CHEMISTRY (2007)
Mutasynthesis - uniting chemistry and genetics for drug discovery
Kira J. Weissman
TRENDS IN BIOTECHNOLOGY (2007)
Exenatide - an incretin mimetic agent for the treatment of type 2 diabetes
H. Reuter et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2007)
Total synthesis approaches to natural product derivatives based on the combination of chemical synthesis and metabolic engineering
Andreas Kirschning et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2007)
Total synthesis of rapamycin
Matthew L. Maddess et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2007)
Cellular targets of natural products
Neil Dixon et al.
NATURAL PRODUCT REPORTS (2007)
Technology Insight: cytotoxic drug immunoconjugates for cancer therapy
Alejandro D. Ricart et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin
Donnette A. Dabydeen et al.
MOLECULAR PHARMACOLOGY (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
DK Ro et al.
NATURE (2006)
Total synthesis and evaluation of [ψ[CH2NH]Tpg4]vancomycin aglycon:: Reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding
BM Crowley et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Antibacterial natural products in medicinal chemistry - Exodus or revival?
Franz von Nussbaum et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Synthesis of (-)-tetracycline
MG Charest et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
FKBP immunophilin patents for neurological disorders
RE Babine et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2005)
A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics
MG Charest et al.
SCIENCE (2005)
Production of novel rapamycin analogs by precursor-directed biosynthesis
FV Ritacco et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2005)
The evolving role of natural products in drug discovery
FE Koehn et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
DL Higgins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Glycopeptide and lipoglycopeptide antibiotics
D Kahne et al.
CHEMICAL REVIEWS (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis
MA Gregory et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
The impact of bacterial genomics on natural product research
HB Bode et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424)
MR Leadbetter et al.
JOURNAL OF ANTIBIOTICS (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Glycopeptide antibiotics from conventional molecules to new derivatives
F Van Bambeke et al.
DRUGS (2004)
Recent developments in the maytansinoid antitumor agents
JM Cassady et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2004)
Macrocyclic ketone analogues of halichondrin B
WJ Zheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Structurally simplified macrolactone analogues of halichondrin B
BM Seletsky et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
A medicinal chemistry perspective on artemisinin and related endoperoxides
PM O'Neill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus
LM Weigel et al.
SCIENCE (2003)
Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics
D Mendola
BIOMOLECULAR ENGINEERING (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
The development of immunosuppression: The rapamycin milestone
RY Calne
TRANSPLANTATION PROCEEDINGS (2003)
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene
S Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
From natural products to clinically useful antifungals
D Barrett
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance
I Chopra et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2001)
FR131535, a novel water-soluble echinocandin-like lipopeptide: Synthesis and biological properties
A Fujie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Limitations of presently available glycopeptides in the treatment of Gram-positive infection
HM Ziglam et al.
CLINICAL MICROBIOLOGY AND INFECTION (2001)
The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit
DE Brodersen et al.
CELL (2000)
Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B
C Cuevas et al.
ORGANIC LETTERS (2000)
A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents
EJ Martinez et al.
ORGANIC LETTERS (2000)
Share Paper
